Objective: The specific objective of this investigation was to determine whether bronchopulmonary responsiveness (BPR) to methacholine (MCH) was associated with the body mass index (BMI) of Tunisian women. Subjects: In all, 160 healthy nonsmoker women (52 lean, 45 overweight and 63 obese) were recruited and examined in the Clinical Laboratory of Physiology located in the Medical School of Sousse. The average ages ( ± s.e.) of the three categories of lean, overweight and obese subjects were 27.7±1.1, 33.2±1.7 and 37.5±1.3 years, respectively. Their corresponding mean BMIs ( ± s.e.) were 21.9 ± 0.3, 27.7 ± 0.2 and 36.5 ± 0.8 kg m À2 , respectively. Measurements: Before their inclusion into the study, subjects were screened for their lung status by measuring their pulmonary function testing parameters using a whole body plethysmograph. BPR was assessed, using a cumulative concentration response curve technique, by measuring with a spirometer the decrease in forced expiratory volume in 1 s (FEV 1 ) in response to a cumulative dose of MCH. Results: After adjusting for age, significant differences in both FEV 1 and forced vital capacity (VC) were found between the obese and lean groups (Po0.01), as well as between the obese and overweight groups (Po0.01). In addition, forced expiratory flow between 25 and 75% of VC was significantly different between the obese and lean groups (Po0.001), as well as between the lean and overweight groups (P ¼ 0.015). The mean maximum fall of FEV 1 in response to MCH challenge was significantly higher for the obese group (12.0%) than for the overweight (9.8%) or the lean (6.6%) group (Po0.01). Furthermore, the efficacy of the MCH agonist promoting the maximal response (E max ) and its potency or effective dose producing 50% of the maximal response (ED 50 ) were both associated with BMI (the higher the BMI, the higher the E max and the lower the ED 50 ). Conclusion: Our data clearly show that obesity affects pulmonary function performance in Tunisian women by potentially promoting their bronchial hyperreactivity as suggested by the significant correlation between their BMI and the efficacy of the MCH, as well as its potency.
Introduction
It is a well-recognized fact that both obesity and asthma are major public health concerns, and their prevalence has increased tremendously in many countries over the last few decades. 1, 2 Although obesity is a known risk factor for type 2 diabetes and cardiovascular diseases such as hypertension and atherosclerosis, the concurrent increase in the two conditions of obesity and asthma raises the possibility that the two might be linked to each other as suggested by a recent epidemiological review. 3 An important aspect of these epidemiological data is that the impact of obesity on asthma is much stronger in females than in males. Asthma is a complex multifactorial disease characterized by chronic airway inflammation, bronchial remodeling, reversible airflow obstruction and increased airways responsiveness. 4 It affects millions of people worldwide and its prevalence in the United States has doubled in the last 20 years, 5 with the greatest increase seen in African Americans and Hispanics. 6 According to the Centers for Disease Control and Preventions, 7 417 million individuals are affected by asthma, which has increased most rapidly in children who also account for the highest rates of this disease among the population at large. The report also indicates that the prevalence of self-reported asthma for all ages has increased by 74% from 1980 through 1998. Although no national prevalence study on asthma exists in Tunisia, two local teams of Medical Doctors at the health region of Monastir 8 and at the military hospital of Tunis 9 have conducted retrospective investigations on the etiology of chronic diseases. Their data indicate that 31.5% of the observed cases were diagnosed with asthma and diabetes and 40% of the asthmatics were predominantly children. Many countries have witnessed large increases in the prevalence of asthma during the last few decades, including the United States and Tunisia. The reasons for these increases are not well understood, but may be the result of a complex interplay of genetic, environmental, behavioral and socioeconomic factors. Similarly, obesity is suggested to be one factor that may have an important role in the induction and exacerbation or persistence of asthma. 4 Obesity affects as many as a quarter of a billion people worldwide, and B100 million adults in the United States are at least overweight or obese. 10 4 and prevalence is even greater in some minority groups. 10 Data obtained from Tunisia exhibit similar disturbing trends, with obesity rates exceeding 22% in women but only 7% in men. 14 The prevalence of obesity has been increasing since 1980, and although the rate has increased significantly from 8.7% in 1980 to 22.7% in 1997 in women, it has remained low in men. 14 Overweight is on the rise for both sexes attaining alarming levels of 50.9 and 30.3% in women and men, respectively. 14,15 Furthermore, overweight increases with age, and the risk of obesity among Tunisian adolescents is 9.5% in girls and 5.1% in boys.
14 Collectively, there is mounting evidence that obesity is a major risk factor for asthma. Therefore, investigating the mechanism governing the relationship between obesity and asthma incidence and the role of weight management among patients with lung disease has important ramifications for the prevention and treatment of both conditions. Although there were several previous large investigations involving obesity-related asthma and airway hyperresponsiveness, most of them included either unhealthy patients who were usually associated with cardiovascular and respiratory diseases, 16, 17 or subjects who were smokers and exsmokers. 18 Moreover, owing to their epidemiological nature, the investigational approach of those previous studies was based on a health survey of reported symptoms of asthma. 19, 20 The central theme of this study was to test the hypothesis that, by affecting pulmonary function performance and by promoting bronchial hyperreponsiveness to methacholine (MCH) challenge, obesity may potentially increase the incidence and prevalence of asthma. Our research was therefore focused exclusively on healthy nonsmoking groups of women (52 lean, 45 overweight and 63 obese) to investigate whether their sole obesity status impaired their lung function and whether their bronchopulmonary responsiveness (BPR) was associated with their body mass index (BMI). To this end, we used a rigorous pharmacological method to quantitatively determine the efficacy and the potency of the bronchoconstricting agonist in relation to the BMI of our female subjects.
Materials and methods
Subject selection and health screening A total of 160 women (63 obese, 45 overweight and 52 lean subjects) were recruited from Sousse and its suburban small towns by word of mouth. Only females were included in this study because the obesity of males in Tunisia is low, and unlike women, the large majority of men are heavy smokers. Each of the 160 subjects who completed the study were first asked to fill in medical and smoking history forms and then participate in a health screening session and overall medical examination administered by a physician. In addition to measuring their heights, weights and resting arterial blood pressures, blood samples were collected from the participants to determine their fasting serum lipids, glucose and serum insulin.
A subject was not admitted into the study if she had high blood pressure, a medical history of asthma, chronic respiratory, heart or any other diseases. With the exception of birth control pills and vitamin supplements, women who regularly took medication of any kind were excluded from the study. All our participating subjects never smoked cigarettes, and were neither pregnant nor breastfeeding. They were characterized as lean if their BMI was o25 kg m Drugs MCH chloride, a cholinergic neurotransmitter analog of acetylcholine, showed greater duration and selectivity of action than did the parent compound and was well tolerated without producing systemic effects. 21, 22 Owing to stability constraints, MCH was distributed (SigmaAldrich, Steinheim, Germany) as a crystalline powder in sterile and sealed vials, and was kept refrigerated in desiccators. The nebulized solutions were prepared with sterile saline and stored at 4 1C to avoid contamination and decomposition.
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Biochemical assays
Blood samples were collected into EDTA-containing tubes, chilled promptly in an ice bath and the plasma and serum were separated immediately by centrifugation at 3100 r.p.m. at 4 1C, and at 1000 r.p.m. at room temperature for 10 min, respectively. Samples were stored at À80 1C until assayed. At the time of analysis, routine chemical methods were used to determine serum concentrations of insulin, total cholesterol, high-density lipoprotein-cholesterol, triglycerides and glucose. The serum concentration of low-density lipoprotein was estimated using Friedewald's method. 23 Lung function tests and MCH challenge To screen subjects for their respiratory performance conditions, their pulmonary function testing parameters, including forced expiratory volume in 1 s (FEV 1 ), forced vital capacity (FVC) and mean FEF 25À75 (forced expiratory flow between 25 and 75% of VC), were measured using a commercial whole body plethysmograph (ZAN Messgerate GmbH, Oberthulba, Germany).
To undergo a MCH challenge test, the results of the subject's pulmonary function testing had to be within normal limits, defined as an FEV 1 /FVC ratio 475% of the predicted Knudsen value. 24 The MCH challenge test is a standard clinical method for assessing lung airways responsiveness. As a first step, the subject started breathing saline as a control solution, and then inhaled MCH in ascending aerosolized doses. 25, 26 The aerosolization of MCH was produced by an air-compressed nebulizer, and the inhalation of the bronchoconstrictor was achieved using an FDC 88 dosimeter (MEDIPROM, Paris, France). As the nebulizer was equipped with a solenoid valve, the opening of which occurred only during inspiration, the subject was instructed simply to breathe the aerosolized bolus of MCH through the nebulizer at her VC. The inhalation of MCH was performed successively every 5 min in cumulative doses ranging from 100 to 3000 mg. Thirty and ninety seconds after each MCH bolus inhalation, BPR was assessed twice by measuring the decrease in FEV 1 in response to the cumulative doses of the bronchoconstricting agonist, using a commercial spirometer (Minato Medical Science Co, Ltd., Osaka, Japan). The best value of the two measurements of FEV 1 was retained at the end. A cumulative concentration response curve was then obtained for each subject. The cumulative concentration response curve data of each subject were then plotted on a semi-log 10 scale curve to determine two quantitative response parameters characterizing the BPR of each subject:
(1) the efficacy of the MCH agonist promoting the maximal response (E max ); and (2) its potency or effective dose producing 50% of the maximal response (ED 50 ). E max was determined from the plateau of the dose-response curve, and ED 50 was estimated from the position on the approximate sigmoid curve corresponding to 50% of the plateau.
Statistics
Multigroup comparisons of variables were carried out using the Statistical Package for the Social Sciences software (Chicago, IL, USA). Two-tailed Student's t tests were used to analyze differences in response parameters between obese, overweight and lean subjects. The strengths of the relationships between BPR parameters and BMI were characterized with Pearson's correlation coefficients (r). In all statistical tests, the level of significance was set at P ¼ 0.05.
Results
Of the 160 subjects who were included in this study, 33% were lean, 28% were overweight and 39% were obese women. Table 1 contains an analysis of the baseline values 
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A Chouchane et al of anthropometrical, physiological and clinical characteristics, each pooled for the 52 lean, 45 overweight and 63 obese women. With the exception of high-density lipoproteincholesterol in which there were no significant differences between the three groups, the other physical, clinical and biochemical parameters exhibited significantly higher values in obese than in overweight and lean subjects. However, all of these data were within the normal range of healthy individuals.
On the other hand, the adjusted means for the pulmonary function performance, which include FEV 1 , FVC and FEV 1 /FVC ratios, and FEF 25À75 , were significantly lower in obese than in overweight and lean subjects (Table 1) . However, when these lung function parameters were normalized by the predicted values, the statistical differences between the three groups of subjects disappear. This could be due to the fact that our obese and overweight subjects were as healthy as our lean subjects with respect to the baselines of their lung function in relation to the normal predicted Knudsen values 24 that take into account not only the age but also the height of the subjects. Although there were significant differences between the groups in age, statistical analysis showed that this factor has no significant effects on the BHR responses of our subjects. It suggests that the age difference among our three groups of women was not large enough to be a determining factor.
Results for the BPR of the three groups of women to cumulatively increasing doses of MCH are graphed in Figures  1 and 2 . Judging from these plots, three convergent and prominent features associating obesity with BPR can be singled out: (1) the cumulative concentration response curve data points in Figure 1 illustrate that the decrease in FEV 1 , averaged for all subjects over the explored range of MCH doses, was consistently more pronounced in the obese than in the overweight and lean subjects; (2) whereas the overall mean maximum fall in FEV 1 (efficacy or E max ) induced by MCH challenge (Figure 2 ) was significantly higher in the obese group (12%) than in the overweight (9.8%) or lean group (6.6%), the potency of MCH (ED 50 ) (Figure 2 ) was significantly lower in the obese than in the overweight or lean subjects; and (3) the positive correlation of the efficacy of MCH and the negative correlation of its potency with BMI ( Figure 2) show that obesity altered these two important BPR indicators. Collectively, our results suggest that obesity may have an important role in developing airway hyperreactivity and possibly asthma.
Discussion

MCH challenge test and BMI
Testing of airway hyperreactivity has always been a challenging task when it is used to determine whether a patient could be diagnosed with asthma. This is due to the fact that a good proportion of individuals who might respond positively to the challenge test were asymptomatic. 28, 29 Nevertheless, increased BPR to bronchoconstrictive stimulation is usually a good indicator for the potential development of asthma. 30 Our data clearly indicate that both the efficacy (E max ) of MCH and its potency (ED 50 ) are correlated with the BMI of our female subjects. As these two E max and Effect of obesity on airway hyperreactivity A Chouchane et al ED 50 parameters are good indicators of bronchopulmonary hyperreactivity, which is in turn a good indicator of the potential development of asthma, it is reasonable to speculate that our obese and overweight groups may potentially develop asthma if their weight is not effectively managed preventively with time.
In a study of 670 Korean children aged 10-13 years, BMI was not a significant predictor of airway hyperresponsiveness determined from a MCH challenge test. 31 This is not surprising because the dynamic evolution of children's BMI may change disproportionally in weight and height until they reach the age of 20-21 years. On the other hand, as only the weight of adults may increase or decrease over time by affecting their BMI, this latter factor is considered to be a more reliable index of obesity for adults than for children. Several reports have indicated that an increase in BMI could be associated with an increase in the prevalence of asthma, especially in women. 32, 33 On the other hand, a Chilean study of a large population 20 reported no association between wheeze and BMI in their female subjects and found mixed results regarding the association between asthma symptoms and obesity whether using waist circumference or BMI.
Comparison with other studies Using spirometry tests, Spathopoulos et al. 34 investigated the effect of obesity on lung function performance in a large cohort of Greek children aged 6-11 years. Similar to our female adult data, their results indicated that all the pulmonary function parameters, including FEV 1 , FVC, FEV 1 /FVC and FEF 25À75 , were significantly reduced in overweight or obese children compared with normal weight children (P ¼ 0.007, Po0.001, Po0.001 and Po0.001, respectively). It is also interesting to observe that, contrary to the Korean study, the Greek investigation showed that high BMI was an important determinant of reduced spirometric parameters. Camargo et al. 35 carried out one of the first longitudinal studies in adults, showing that women who gained weight after 18 years of age ran a greater risk of developing asthma in the next 4 years, regardless of their caloric intake or physical activity. In recent years, several epidemiological studies on adults and children have suggested a possible association between obesity and the incidence and prevalence of asthma, primarily among females, and independently of diet, physical activity or allergic condition. 36 For instance, Chang et al. 37 observed coincidentally that a significant number of Korean women, who were diagnosed with asthma or complained about asthma-related symptoms, were obese. Although there were several previous large investigations involving obesity-related asthma and airway hyperresponsiveness, most of them included either unhealthy patients who were usually associated with cardiovascular and respiratory diseases, 16, 17 or subjects who were smokers and ex-smokers. 18 Moreover, owing to their epidemiological nature, the investigational approach of those previous studies was based on a health survey of reported symptoms of asthma. 19, 20 To the best of our knowledge, this is the first study to investigate quantitatively the direct association between BPR and BMI in healthy women. Unlike previous studies, our research was rather exclusively focused on healthy nonsmoking young subjects, and used a unique rigorous pharmacological method to quantitatively determine the relationship between the efficacy and as the potency of MCH, two good indicators of BPR, and the BMI of our well-defined female subjects. Effect of obesity on airway hyperreactivity A Chouchane et al
As airway smooth muscle cells are the key end effectors of acute airway narrowing, it is logical to determine whether obesity has an impact on airway smooth muscle function and airway responsiveness. Our results clearly show that obesity increased the BPR to MCH challenge and induced alterations in the efficacy and the potency of this cholinergic agonist. Although the decreases in expiratory reserve volume and forced reserve capacity are proportionate to the degree of obesity, dynamic lung volumes including VC and total lung capacity are often normal. 38, 39 Therefore, it appears that spirometric abnormalities in patients with mild-to-moderate obesity represent a restrictive defect placed on the system, whereas airflow obstruction may result from severe and morbid obesity. The pattern of body fat distribution may also influence the effect of obesity on lung function. It is generally believed that upper body obesity carries a higher risk of cardiovascular and metabolic disease than lower body obesity, suggesting that central abdominal obesity has a greater impact on spirometric parameters than back or lower body obesity.
Potential mechanisms of obesity-asthma relationship
In addition to epidemiological studies indicating an increased prevalence of asthma in obese subjects, 40, 41 some investigators have proposed immunological and inflammatory mechanisms, 42, 43 as well as mechanical mechanisms 44, 45 by which obesity could interact with asthma. For instance, the adipose tissue produces and releases two hormones, leptin and adiponectin, that exert proinflammatory 46 and anti-inflammatory roles, 47 respectively. Interestingly, serum leptin is known to increase markedly in obesity, 48, 49 and is found at higher levels in asthmatics than in nonasthmatics, 50 regardless of the extent of obesity. In contrast, serum adiponectin levels have the tendency to be reduced in obese subjects. 51 Changes in airway structure and function have also been associated with obesity. 43 For example, increased abdominal and chest wall mass in obese individuals causes reduced functional residual capacity, 48 a major determinant of airway diameter. 52 Consequently, it is likely that obesity-related changes in forced reserve capacity unload the airway smooth muscle cells, thereby allowing them to shorten excessively when activated. Further evidence of a direct association between obesity and airway hyperreactivity has been shown in an experimental study in which ozone-induced airway hyperreactivity and bronchial inflammation in obese mice were more pronounced than that observed in lean wild-type mice. 53 Obesity generally increases the production of estrogens, which are associated with early menarche in girls and delayed puberty in boys. 54, 55 In the Tucson cohort, CastroRodriguez et al. 56 observed the prevalence of asthma to be greater among obese girls with early menarche (before 11 years of age) than among those with later menarche. This would indicate that obesity alters the production (or peripheral sensitivity) of the hormones associated with puberty in girls and that the increased production of female hormones (or their sensitivity) alters the lung development and regulation of airway tone in puberty-age girls. This finding was confirmed in a study in adults in France where Varraso et al. 57 observed that the association between obesity and asthma was more evident among women with early menarche.
In conclusion, we have shown that obesity not only affected the basic pulmonary function performance of our female subjects but also induced a significant alteration in the efficacy, as well as the potency of their BPR to MCH challenge. This is an indication that our obese patients may be prone to become either hyperreactive or asthmatic.
Work in progress
To better understand the mechanisms and potential causes of obesity-induced BPR, our future research will focus on investigating whether our patients have developed or are developing conditions of inflammation by measuring their cytokines in the blood and by forced expectoration. Indeed, obesity and asthma are believed to share common inflammatory conditions, with increased levels of several inflammatory markers, including leptin, tumor necrosis factor-a, interleukin-4, interleukin-5, interleukin-6 and interleukin-12. 44 There is also evidence that obesity is a 'proinflammatory' state. 44, 58 Leptin, a Lep gene protein, which is a hormone produced by adipocytes that acts on the hypothalamus to signal satiety and increase resting metabolism, 59 has receptors in the human lung tissue and provides a link between inflammation and Tcell function in asthma. 44, 60 
